Comparison Study Of Lucentis, Avastin And Eylea In DME Starts With NIH Funding
This article was originally published in The Pink Sheet Daily
The study’s sponsor, the NIH-funded Diabetic Retinopathy Clinical Research Network, highlighted the cost disparity between treatments for diabetic macular edema in a summary of the study’s purpose.
You may also be interested in...
The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.
FDA approves lower, monthly 0.3 mg dose of injectable Lucentis for diabetic macular edema, the regimen Genentech had suggested was most appropriate. Questions remain about the commercial picture, considering competition from the similar but much cheaper Avastin.